Merck & Co Inc (NYSE:MRK)
| 94.64 Delayed Data As of May 24 |  +0.81 / +0.86%Today’s Change | 70.89 Today|||52-Week Range 94.92 | +23.49% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $236.6B |
Company Description
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
Contact Information
Merck & Co., Inc. 2000 Galloping Hill Road Kenilworth New Jersey 07033 |
Employees
Shareholders
| Mutual fund holders | 38.02% |
| Other institutional | 37.03% |
| Individual stakeholders | 0.14% |
Top Executives
| Robert M. Davis | President, Chief Executive Officer & Director |
| Caroline A. Litchfield | Chief Financial Officer & Executive Vice President |
| Dave Williams | EVP, Chief Information & Digital Officer |
| Lisa LeCointe-Cephas | Chief Ethics & Compliance Officer, SVP |
| Richard R. DeLuca | Executive Vice President & President-Animal Health |
